drugset / Trial / NCT07083154
GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)
Phase 3
Recruiting
420 enrolled
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Changzhou No.2 People's Hospital · collabHuadong Hospital · collabJiangsu Province Hospital of Traditional Chinese Medicine · collabNanjing First Hospital, Nanjing Medical University · collabShanghai General Hospital, Shanghai Jiao Tong University School of Medicine · collabThe Second Affiliated Hospital of Dalian Medical University · collabXiangya Hospital of Central South University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The LIGHT-COG study is a 76-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. A total of 420 type 2 diabetes patients with early dementia are randomized 1:1 to either the active treatment group (receiving subcutaneous injections of mazdutide weekly, with stepwise dose escalation to a maintenance dose per protocol) or the placebo group (receiving matched placebo injections). The primary objective is to evaluate the potential disease-modifying effects of mazdutide on cognitive dysfunction in type 2 diabetes.
Timeline
- Start
- 2025-09-27
- Primary completion
- 2029-08-01
- Completion
- 2029-08-01